ORPOF News and Press, OSE Immunotherapeutics SA

OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis Lusvertikimab demonstrates significant efficacy during the 10 week-induction phase of treatment, in the randomized double-blind CotiKis phase 2 study...

Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371 Ingelheim, Germany and Nantes, France, 3 July 2024 – Today Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage ...

OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’ Nantes, France – July 1 st , 2024 – 7:30 am CET – OSE Immunotherapeutics SA (ISIN: FR...

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies NANTES, France, June 24, 2024 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , today announced that the Company has entered into a commercial ...

OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21) NANTES, France, June 20, 2024 – 7:30am CET - OSE Immunotherape...

OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic C ompany’s Growth Nantes, France – June 19, 2024, 6:15pm CET – OSE Immunotherapeutics SA (ISIN: F...

OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in Non-Small Cell Lung Cancer by Dr Stephen Liu and Prof Benjamin Besse NANTES, France, June 12, 2024 – 6:00pm CET In this webinar, OSE Immunotherapeutics joins key opinion ...

OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant At the American Transplant Congress 2024 (June 1-5 Philadelphia) Nantes, France – June 5, 2024, 7:30am CET – OSE Immu...

OSE Immunotherapeutics Provides Business and Corporate Update Three pharmaceutical agreements signed during the last three months: New strategic partnership with AbbVie for OSE-230, a novel preclinical potential first-in-class program for the treatment of chronic inflammation. ...

OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective NANTES, France, April 16, 2024 – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, to...